Gensight Biologics SA

G49N

Company Profile

  • Business description

    Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.

  • Contact

    74, rue du Faubourg Saint-Antoine
    Paris75012
    FRA

    T: +33 176217220

    https://www.gensight-biologics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2024

    Employees

    46

Stocks News & Analysis

stocks

What did Morningstar subscribers buy and sell during October?

And what do our analysts think of the investments?
stocks

Undervalued and beaten down ASX share appoints new leadership

New CEO has relevant experience in business transformation.
stocks

Berkshire Hathaway earnings: Cash stockpile hits record; Share repurchases nonexistent

Maintaining our fair value estimate on Berkshire stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,456.0068.200.81%
CAC 407,518.73111.581.51%
DAX 4019,442.11185.840.97%
Dow JONES (US)42,221.88427.281.02%
FTSE 1008,278.80106.411.30%
HKSE20,538.38468.59-2.23%
NASDAQ18,439.17259.191.43%
Nikkei 22539,480.671,005.772.61%
NZX 50 Index12,649.179.13-0.07%
S&P 5005,782.7670.071.23%
S&P/ASX 2008,199.5067.700.83%
SSE Composite Index3,383.813.18-0.09%

Market Movers